CD274 and non-small cell lung carcinoma: In the base case analysis (i.e. assuming time-varying HR via fractional polynomial model NMAs) of first-line treatments in patients with locally advanced or metastatic NSCLC with PD-L1 ⩾50%, cemiplimab demonstrated comparable OS and statistically significant improvements in PFS from 6 to 30 months versus pembrolizumab, with no evidence of difference in Grade 3–5 all-cause AEs, IMAEs, and all-cause DAEs.